Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Lockdowns made people feel isolated, depressed, and anxious, leading some to increase their alcohol intake.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.
Nearly 200 cases of pediatric hepatitis have now been reported in more than a dozen countries and several states.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
While vaccination typically provides robust protection against severe disease, they’re less effective for immunocompromised people.
Immunocompromised people ages 12 and older are also eligible for an additional shot.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
Boosters reduced the risk of hospitalization and death by about 80% for people with HIV, cancer, autoimmune conditions or organ transplants.
Organ transplant recipients take immunosuppressive drugs that impair immune response to pathogens and vaccines.
Experts recommend no more than two drinks for men or one drink for women per day.
Boosters further reduce the risk of severe illness and can help curb coronavirus transmission.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
A growing number of transplant programs are barring patients who refuse COVID vaccines or giving them lower priority on waiting lists.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.